XGene Regulatory Intelligence Platform
Connect enforcement signals to quality systems, services, expert commentary, and implementation resources.
ICH Q2(R2) and its companion ICH Q14 were finalized in November 2023 as a paired guideline set that fundamentally reframes analytical method validation — not as a one-time compliance event but as a lifecycle
View details →
In gene therapy manufacturing, impurity profiles are largely determined before fermentation begins. The raw material and starting material strategy you define at IND becomes the compliance liability you manage at BLA.
View details → Real-time release testing is the regulatory mechanism by which a drug product manufacturer replaces end-product testing with real-time process measurements. FDA has approved RTRT programs across multiple drug product classes, and ICH Q8(R2) explicitly
View details → The viral safety package for a gene therapy vector is not analogous to a standard biologics viral clearance study. CBER evaluates it differently — and the gaps are rarely apparent until a clinical hold.
View details →
ICH Q14 and the updated ICH Q2(R2) represent the most significant change to pharmaceutical analytical regulatory science since Q2(R1) was issued in 1994. They introduce a lifecycle approach to analytical procedures — from development
View details → No single analytical question in AAV CMC generates more CBER comments than the full/empty capsid ratio. And yet most early-stage packages treat it as a secondary characterization attribute.
View details → ICH Q13 became a finalized international guideline in 2022 and was implemented by FDA and EMA in short succession — making it the first ICH guideline that fully addresses continuous manufacturing as a primary
View details → The drug product section of a GT CMC package is where physics, chemistry, and virology converge. An AAV or lentiviral vector that survives manufacturing can still fail at fill/finish if formulation development was not
View details → Breakthrough Therapy Designation does not accelerate FDA's CMC review standards. It accelerates the clinical program, compresses the development timeline, and brings the NDA filing date forward — often to a point where the CMC
View details → Every gene therapy lot that goes into a patient was released against a specification. Whether that specification can be defended at BLA — across all lots, all timepoints, all analytical method versions — is
View details → FDA's Accelerated Approval pathway has approved more than 250 drugs since 1992. The clinical story dominates the regulatory narrative. What almost never appears in that narrative is the CMC post-marketing commitment architecture — the
View details → A gene therapy stability program is not a stability program until it measures the right attributes at the right timepoints. Most early-stage GT stability programs measure the convenient attributes, not the critical ones.
View details → FDA formal meetings are among the most consequential strategic decisions in drug development, and most CMC teams use them incorrectly. Not because they fail to request them — Type B End-of-Phase 2 meetings are
View details → Lentiviral vectors integrate into the host genome. That single biological fact shapes every CMC expectation CBER has for your drug substance — from the design of your packaging system to your RCL testing strategy.
View details → A sponsor who walks out of a pre-NDA FDA meeting with confirmed minutes stating that their proposed bispecific antibody potency specification is acceptable has converted 60 minutes into regulatory protection against a deficiency letter.
View details → The Quality Overall Summary for a gene therapy product is the document CBER reviewers read first. It either demonstrates integrated CMC understanding or reveals the gaps before they open Module 3.
View details →
A Complete Response Letter with CMC deficiencies is not a list of things FDA wants you to add to your submission. It is a precisely worded document in which every deficiency represents a specific
View details →
The FDA's 2011 Process Validation Guidance was written for the pharmaceutical industry. Applying it to a GT vector manufacturing process requires translation — and where that translation is missing, PPQ failures follow.
View details →